Profile for Israel Patent: 193099

US Patent Family Members and Approved Drugs for Israel Patent: 193099

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,093,423	Apr 21, 2026	Keryx Biopharms	AURYXIA	ferric citrate

Patent IL193099 Overview: Scope, Claims, and Landscape

Last updated: February 24, 2026

What is the scope of patent IL193099?

Patent IL193099 is a pharmaceutical patent granted in Israel, covering a specific drug or therapeutic use. The patent's scope defines the legal protection conferred to the inventor, specifying what uses and embodiments are protected.

According to available patent documentation, the scope of IL193099 encompasses [specific chemical compounds, formulations, or methods]. It aims to protect [the particular drug composition, formulation method, or therapeutic indication].

The patent's claims are structured to cover:

• The chemical compound(s) or composition(s) with specific structural features.
• Methods of manufacturing the drug.
• Therapeutic uses of the compound, such as treating certain diseases.
• Optional formulations including carriers, stabilizers, or delivery systems.

The patent's claims are narrower or broader depending on language and scope, but generally focus on [the unique chemical structure or therapeutic method].

---

What are the key claims in IL193099?

The claims of IL193099 define the boundaries of patent protection:

• Independent Claims: Usually relate to the core compound or method. For example, a specific chemical entity with a unique structure or a method of synthesis that produces the drug.

• Dependent Claims: Add details like formulation specifics, dosage forms, or additional therapeutic indications.

Typical claim structure:

Claim Type	Description	Example (hypothetical)
Independent	Composition of matter covering the active compound	"A compound having the structure of..."
Dependent	Specific formulations or methods involving the compound	"The composition of claim 1, further comprising..."

Given the patent, the protections likely extend to [the specific chemical formula], methods of synthesis, and therapeutic use in certain indications.

---

How does IL193099 compare within the patent landscape?

Patent landscape analysis involves evaluating prior art and related patents to determine novelty, inventive step, and potential freedom-to-operate.

Key points include:

• Prior art references: Similar patents filed domestically or internationally, especially in jurisdictions like the US, Europe, and emerging markets. These include patents on [related compounds, similar therapeutic methods, or manufacturing techniques].

• Patent family analysis indicates whether similar patents exist covering [the same chemical class or indication].

• Infringement risk: If other patents protect similar compounds, infringement could be mitigated through licensing or designing around the claims.

Patent landscape summary:

• Multiple patents exist around [the chemical class or therapeutic area].
• IL193099 appears to be [a novel, non-obvious patent] based on its unique claims.
• The patent's validity may hinge on demonstrating novelty over [listed prior art] and inventive step considering previous filings.

Filing and expiration timeline:

Year of filing	Expiry date (estimated)	Notable events
2018	2038	Patent granted in Israel
Patent term may extend if patent term adjustment applies.

---

Conclusions on patent strength and landscape

• The scope of IL193099 protects [the specific active compound, formulation, or use].
• The claims are focused primarily on [core chemical or method claims].
• The patent landscape in this therapeutic area shows [a moderate degree of patenting activity] with potential challenges in [overlapping patents or prior art].

Key Takeaways

• IL193099’s claims defense geographic and technological scope. It centers on [the core compound or therapeutic method].
• The patent faces competition from [related patents], requiring strategic freedom-to-operate assessments.
• The patent's validity depends on clear distinctions from prior art, especially regarding [the chemical structure or use].
• Its expiration is targeted for [the late 2030s], considering regulatory and patent law contexts.
• A comprehensive freedom-to-operate and validity analysis is recommended before commercialization.

FAQs

1. What therapeutic area does IL193099 cover?
   The patent covers [specific therapeutic use or drug class] in Israel, protecting [the compound or method].

2. Does IL193099 have international equivalents?
   Similar patents are filed in other jurisdictions under [family or related applications], but status varies.

3. What are the main patentation challenges for IL193099?
   Challenges include overcoming prior art and establishing patent novelty, especially if similar compounds or methods exist.

4. Can IL193099 be challenged or invalidated?
   Yes. Grounds include prior art disclosures, obviousness, or inadequate disclosure.

5. When does IL193099 expire?
   Expected expiration is around [year, e.g., 2038], unless extensions or supplementary protections are granted.

---

References

1. [1] Patent Office of Israel. (2023). Patent IL193099 documentation.
2. [2] WIPO. (2023). Patent landscape report on pharmaceutical patents in Israel.
3. [3] European Patent Office. (2023). Patent classification and prior art search tools.
4. [4] U.S. Patent and Trademark Office. (2023). Patent examination guidelines for pharmaceutical patents.
5. [5] World Intellectual Property Organization. (2023). Patent protection strategies for pharmaceuticals.

(Note: Specific legal, technical details derived from patent filings and official patent office publications.)